Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Coenzyme Q10

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 272Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    The first potent COQ8 inhibitor targets ubiquinone biosynthesis
    The first potent COQ8 inhibitor targets ubiquinone biosynthesis

    28 Nov 2022

    // HIPPOCRATICPOST

    https://www.hippocraticpost.com/screening/the-first-potent-coq8-inhibitor-targets-ubiquinone-biosynthesis/

    HIPPOCRATICPOST
    28 Nov 2022
    Share Share
    Health Canada Recalls Pharm Canada's Passion Fem Capsules; Natura-One Passion Fem Capsules
    Health Canada Recalls Pharm Canada's Passion Fem Capsules; Natura-One Passion Fem Capsules

    07 Oct 2019

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/health-canada-recalls-pharm-canadas-passion-fem-capsules-natura-one-passion-fem-capsules-1570514947.pdf

    HEALTH CANADA
    07 Oct 2019
    Share Share
    Enforcement Report - Week of April 25, 2018
    Enforcement Report - Week of April 25, 2018

    25 Apr 2018

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-25-2018-1524633895.pdf

    FDA
    25 Apr 2018
    Share Share